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Abstract
Metabolic engineering has recently been embraced as an effective tool for developing whole-cell
biocatalysts for oligosaccharide and polysaccharide synthesis. Microbial catalysts now provide a
practical means to derive many valuable oligosaccharides, previously inaccessible through other
methods, in sufficient quantities to support research and clinical applications. The synthesis process
based upon these microbes is scalable as it avoids expensive starting materials. Most impressive is
the high product concentrations (up to 188 g/L) achieved through microbe-catalyzed synthesis. The
overall cost for selected molecules has been brought to a reasonable range (estimated $ 30–50/g).
Microbial synthesis of oligosaccharides and polysaccharides is a carbon-intensive and energy-
intensive process, presenting some unique challenges in metabolic engineering. Unlike nicotinamide
cofactors, the required sugar nucleotides are products of multiple interacting pathways, adding
significant complexity to the metabolic engineering effort. Besides the challenge of providing the
necessary mammalian-originated glycosyltransferases in active form, an adequate uptake of sugar
acceptors can be an issue when another sugar is necessary as a carbon and energy source. These
challenges are analyzed, and various strategies used to overcome these difficulties are reviewed in
this article. Despite the impressive success of the microbial coupling strategy, there is a need to
develop a single strain that can achieve at least the same efficiency. Host selection and the manner
with which the synthesis interacts with the central metabolism are two important factors in the
design of microbial catalysts. Additionally, unlike in vitro enzymatic synthesis, product degradation
and byproduct formation are challenges of whole-cell systems that require additional engineering.
A systematic approach that accounts for various and often conflicting requirements of the synthesis
holds the key to deriving an efficient catalyst.
Metabolic engineering strategies applied to selected polysaccharides (hyaluronan, alginate, and
exopolysaccharides for food use) are reviewed in this article to highlight the recent progress in this
area and similarity to challenges in oligosaccharide synthesis. Many naturally occurring microbes
possess highly efficient mechanisms for polysaccharide synthesis. These mechanisms could
potentially be engineered into a microbe for oligosaccharide and polysaccharide synthesis with
enhanced efficiency.
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Review
Oligosaccharides and polysaccharides are found in nature
as components of a broad range of molecular structures,
such as cell surface glycoproteins and glycolipids. Carbo-
hydrate moieties of these structures play vital roles in cel-
lular communication processes, as points of attachment
for antibodies and other proteins, and as receptors for
bacteria and viral particles [1]. Oligosaccharides and
polysaccharides therefore have enormous potential as
therapeutic agents. However, this potential is far from
being realized due to the complex structure of oligosac-
charides which makes classical chemical synthesis diffi-
cult [2]. Biocatalytic strategies, using either enzymes or
whole-cells, represent a realistic and scalable approach to
the enormous challenges in synthesizing complex carbo-
hydrates. In this review, we focus on advances made in
recent years in developing efficient microbial whole-cell
catalysts through metabolic engineering. Due to space
limitations, enzymatic approaches, where isolated
enzymes are used, are not covered here. Several recent
reviews provide excellent overviews of research activities
utilizing the enzymatic approach [3-7].
Oligosaccharide structures synthesized with 
metabolically engineered microbes
Metabolic engineering of microbial cells represents one of
the most promising strategies for deriving oligosaccha-
rides in sufficient quantities to support research and clin-
ical development. Structures synthesized using
metabolically engineered microbes reported in literature
since 1998 were surveyed and are tabulated in Table 1 (see
Additional file 1). Oligosaccharides, di-, tri-, tetra-, and
penta-saccharides of diverse structures were successfully
synthesized with engineered Escherichia coli, Pichia pas-
toris, Agrobacterium sp. Corneybacterium ammoniagenes, and
Corneybacterium glutamicum. The sugar nucleotide regener-
ation is central to these metabolic engineering efforts, and
many ingenious methods were developed. Depending on
the specific sugar nucleotide, the methods vary considera-
bly in the degree of complication. With only one excep-
tion (truncated bovine α-1,3-galactosyltransferase), these
syntheses exploited microbial glycosyltransferase
enzymes, many of which were originated from microbial
pathogens. One important advantage of the whole-cell
approach is the scalability. Since it avoids expensive start-
ing materials and enzyme isolation, once the strain is
developed, it can be easily scaled-up in a fermentor to pro-
duce the needed quantity of compounds. This is reflected
in the scale of synthesis that has been carried out (up to 2
L, Table 1; see Additional file 1). Product concentration
was also impressive, especially in the microbial coupling
approach. A concentration as high as 188 g/L (372 mM),
highest ever reported for oligosaccharides, was obtained
[8].
The following sections detail various metabolic engineer-
ing strategies used in providing the necessary elements for
synthesis (donors, acceptors, glycosyltransferases). In
addition, several unique metabolic engineering chal-
lenges in oligosaccharide synthesis are analyzed.
Donors
Donor (or sugar nucleotide) provision in oligosaccharide
synthesis is very challenging. The sheer number of
enzymes involved in the synthesis of a sugar nucleotide
makes an enzymatic approach less desirable for large-scale
synthesis. Consequently, whole-cell catalysts were
adopted for their virtue of facile cofactor provisions.
UDP-glucose
Since UDP-glucose is a precursor in cell wall biosynthesis,
all bacteria are capable of its synthesis, at least at a basal
level. Although UDP-glucose has not directly been used in
oligosaccharide synthesis, its efficient regeneration is
important as a precursor for synthesis of other sugar
nucleotides such as UDP-galactose and UDP-GA.
UDP-galactose
UDP-galactose is by far the best-studied cofactor. Several
methods were developed to regenerate this important
cofactor. One approach utilizes a sucrose synthase that
activates sucrose with UDP, a glycosylation co-product,
yielding UDP-glucose. UDP-glucose is then converted to
UDP-galactose using a UDP-galactose 4' epimerase (Fig-
ure 1). This approach delineates the synthesis from the
cell's energy metabolism, since UTP is not required in the
cofactor regeneration. Using this method, the product, P1
trisaccharide, could be accumulated up to 50 mM [9]. The
degradation of UDP-glucose seemed to prevent further
increase of the product, and 5 mM of UDP-glucose was
required to start the synthesis. The second approach uses
galactose kinase and glucose-1-phosphate uridyltrans-
ferase (Figure 2). This route requires the cell to use galac-
tose and another monosaccharide such as fructose to
Metabolic pathway for UDP-galactose synthesis using  sucrose synthase [9] Figure 1
Metabolic pathway for UDP-galactose synthesis using 
sucrose synthase [9]. Enzymes – 1: sucrose synthase (SusA), 
2: UDP-glucose 4'-epimerase (GalE), 3: β1,4-galactosyltrans-
ferase (β1,4GalT), 4: α1,4-galactosyltransferase (α1,4GalT).Microbial Cell Factories 2006, 5:25 http://www.microbialcellfactories.com/content/5/1/25
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synthesize UDP-galactose, and UTP is needed to regener-
ate the sugar nucleotide in each cycle of synthesis [8,10].
The third approach is based on E. coli cells' endogenous
UDP-glucose synthesis pathway [11,12]. UDP-glucose is
synthesized from various carbon sources, but most com-
monly, glucose and glycerol (Figure 3). An introduction
of an epimerase will then allow synthesis of UDP-galac-
tose. This route, like the second approach, requires UTP
for regeneration of this cofactor.
CMP-NeuAc
A CMP-NeuAc regeneration system was constructed in an
E. coli K12 strain by deletion of sialic acid aldolase activity
and introduction of CMP-NeuAc synthase (Figure 4). This
system requires feeding of sialic acid, thus glucose cannot
be used. Furthermore, activation of the sugar relies on the
endogenous pool of CTP [13]. This system was success-
fully used to synthesize sialyllactose, with product accu-
mulation of 1.5 g/L after 22 hours of reaction. In a
microbial coupling approach, three bacterial strains were
used to synthesize CMP-NeuAc from NeuAc and orotic
acid. As shown in Figure 5, the Corneybacterium ammonia-
genes DN510 was used to supply the high level of UTP
needed for CTP synthesis. Additionally, one E. coli strain
expressing CMP-NeuAc synthetase and another expressing
CTP synthetase were required [14]. This system allowed
synthesis of 27 mM (17 g/L) CMP-NeuAc, which led to
high production of 3'-sialylactose (33 g/L) when coupled
to a fourth strain expressing a 2,3-sialyltransferase from N.
gonorrhoeae.
GDP-fucose
One strategy for GDP-fucose production is to enhance the
E. coli cell's natural synthesis capacity. This was accom-
plished by overexpressing a positive regulator protein,
RcsA, in the colanic acid (a fucose-containing exopolysac-
charide) synthesis pathway and by inactivating enzymes
involved in GDP-fucose consumption (Figure 6). Collec-
tively, the metabolic engineering strategy re-directs the
flux of GDP-fucose destined for colanic acid synthesis to
oligosaccharide synthesis. Several fucose-containing
products, up to several grams per liter, were obtained with
this approach [15]. A bacterial coupling strategy was also
developed to produce a high level of GDP-fucose (29 mM,
Figure 7). This strategy required four different strains, in
which a high level of GTP was produced from GMP with
Corynebacterim ammoniagenes and precursor, GDP-man-
nose, was produced from mannose with an E. coli strain
overexpressing five enzymes involved in the synthesis.
Conversion of GDP-mannose to GDP-fucose was accom-
plished by coupling with two plasmid-bearing E. coli
NM522 strains expressing GDP-mannose dehydratase
Metabolic pathway for CMP-NeuAc synthesis using CMP- NeuAc synthase [13] Figure 4
Metabolic pathway for CMP-NeuAc synthesis using CMP-
NeuAc synthase [13]. Enzymes – 1: sialic acid permease 
(NanT), 2: sialic acid aldolase (NanA), 3: CMP-NeuAc syn-
thase, 4: α2,3-sialyltransferase, 5: β-galactoside permease 
(LacY).
Metabolic pathway for UDP-galactose synthesis using galac- tokinase and glucose-1-phosphate uridyltransferase [8] Figure 2
Metabolic pathway for UDP-galactose synthesis using galac-
tokinase and glucose-1-phosphate uridyltransferase [8]. 
Enzymes – 1: glucose-1-phosphate uridyltransferase (GalU), 
2: pyrophosphatase (ppa), 3: galactokinase (GalK), 4: galac-
tose-1-phosphate uridyltransferase (GalT), 5: α1,4-galactosyl-
transferase (lgtC).
Metabolic pathway for UDP-galactose synthesis using endog- enous UDP-glucose synthesis pathway [11] Figure 3
Metabolic pathway for UDP-galactose synthesis using endog-
enous UDP-glucose synthesis pathway [11]. Enzymes – 1: 
phosphoglucose isomerase, 2: phosphoglucomutase, 3: UDP-
glucose pyrophosphorylase, 4: UDP-glucose 4'-epimerase.Microbial Cell Factories 2006, 5:25 http://www.microbialcellfactories.com/content/5/1/25
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and an epimerase/reductase, respectively (Figure 7). Pre-
sumably, the number of E. coli strains could be reduced to
one or two to make the process more efficient. 40 mM (21
g/L) of Lewis X was produced by coupling the GDP-fucose
regeneration system with another E. coli strain expressing
the α1,3-fucosyltransferase from Helicobacter pylori [16].
Another approach was developed in Sacchromyces cerevi-
siae by taking advantage of the inherently high manno-
sylation capability and therefore high level of GDP-D-
mannose in this organism. Two E. coli genes, encoding
GDP-mannose-4,6-dehydratease and a bifunctional GDP-
4-keto-6-deoxy-D-mannose-3,5-epmerase/4-reductase,
were introduced into the host to endow the yeast strain
with the ability to convert GDP-mannose to GDP-fucose
(Figure 8). This approach allowed accumulation of 0.2
mg/L (0.35 µM) of GDP-fucose [17]. Although an in vivo
fucosylation was not demonstrated, it could be expected
when combined with a requisite fucosyltransferase.
UDP-GlcNAc
Like UDP-glucose, UDP-GlcNAc is a precursor to cell wall
synthesis. As such, the endogenous UDP-GlcNAc pool can
be directly used for oligosaccharide synthesis, and its
native synthesis pathway can be used for its regeneration
[18].
UDP-GalNAc
The only report on UDP-GalNAc as a donor in oligosac-
charide synthesis was from Samain and coworkers [19]. In
this method, the endogenous UDP-GlcNAc was epimer-
ized to UDP-GalNAc using an UDP-GlcNAc 4'-epimerase
(WbpP) derived from Pseudomonas aeruginosa O6.
Regeneration systems for GDP-Man and UDP-GA have so
far not been described in the literature for oligosaccharide
synthesis. However, strategies developed for GDP-fucose
could also be applied to GDP-Man, a precursor to GDP-
fucose. Similarly, a strategy could be devised for regenera-
Metabolic pathway for GDP-fucose synthesis using bacterial  coupling [16] Figure 7
Metabolic pathway for GDP-fucose synthesis using bacterial 
coupling [16]. Enzymes – 1: glucokinase (Glk), 2: phospho-
mannomutase (ManB), 3: mannose-1-phosphate guanylyl-
transferase (ManC), 4: GDP-mannose-4,6-dehydratase 
(Gmd), 5: GDP-4-keto-6-deoxy-mannose-3,5-epimerase-4-
reductase (WcaG), 6: α1,3-fucosyltransferase (FucT).
Metabolic pathway for CMP-NeuAc synthesis from NeuAc  and orotic acid [14] Figure 5
Metabolic pathway for CMP-NeuAc synthesis from NeuAc 
and orotic acid [14]. Enzymes – 1: CMP-NeuAc synthetase 
(NeuA), 2: α2,3-sialyltransferase, 3: CTP synthetase (PyrG).
Metabolic pathway for GDP-fucose synthesis using natural  GDP-fucose synthesis pathway [15] Figure 6
Metabolic pathway for GDP-fucose synthesis using natural 
GDP-fucose synthesis pathway [15]. Enzymes – 1: phospho-
mannose isomerase (ManA), 2: phosphomannomutase 
(ManB), 3: mannose-1-phosphate guanylyltransferase (ManC), 
4: GDP-mannose-4,6-dehydratase and GDP-4-keto-6-deoxy-
mannose-3,5-epimerase-4-reductase (Gmd, WcaG), 5: puta-
tive UDP-glucose lipid carrier transferase (WcaJ).Microbial Cell Factories 2006, 5:25 http://www.microbialcellfactories.com/content/5/1/25
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tion of UDP-GA by introducing UDP-glucose dehydroge-
nase into the UDP-glucose synthesis pathway.
Acceptors
A unique problem in oligosaccharide synthesis with met-
abolically engineered cells is the entry of acceptor sugars.
The energy requirement of the synthesis (except in the
case of sucrose synthase) necessitates a supply of energy
source, most often glucose. Due to selective uptake of this
energy source, uptake of the acceptor is not efficient. Sev-
eral strategies have been developed to improve acceptor
uptake. Permeabilization by chemical treatment or freeze-
thaw was generally effective in bringing the acceptor sug-
ars (such as lactose and GlcNAc) inside the cells; however,
it dissipates the membrane potential required for energy
metabolism. Acceptor sugars could be generated inside
the cell by introducing suitable enzymes. For example,
Samain et al. developed a method to generate chitin oli-
gosaccharide (acceptor sugar) in-situ, which was then fur-
ther modified to yield chitobiose [18] or was further
elaborated through introduction of LgtB to generate a Lac-
NAc moiety [20]. Another method is through the manip-
ulation of the catabolite operon of the acceptor sugars.
Significant intracellular accumulation of lactose was
achieved by knocking out the lacZ gene (encoding β-galac-
tosidase) while leaving lacY  (lactose permease) intact
[13]. An intracellular lactose accumulation of 7–8 mM
was observed when the extracellular concentration was
14.6 mM (5 g/L). As a result, lactose could serve as the
acceptor for in vivo reactions. Several valuable tri-, tetra-,
and penta-saccharides were successfully synthesized using
this method [13,19].
Byproduct formation
In in vitro enzymatic synthesis, where the supply of donor
and acceptor sugars can be conveniently controlled,
unwanted byproduct formation is not generally a prob-
lem. However, when the synthesis is taking place inside
the cell, many byproducts could arise due to a number of
reasons. Many glycosyltransferases are promiscuous. LgtB
from Neisseria meningitidis, for example, can use GlcNAc
and glucose, among others, as acceptors, leading to syn-
thesis of LacNAc and lactose, respectively [12]. Although
GlcNAc is a slightly favored acceptor as compared to glu-
cose, under in vivo conditions, the presence of glucose
could lead to a condition that greatly favors the synthesis
of lactose. Lactose formation is detrimental to the synthe-
sis process not only causing purification issues, but also
draining the UDP-galactose and UTP pools [12], which
could otherwise be channeled into LacNAc synthesis.
Interaction of oligosaccharide synthesis with 
central metabolism
With the exception of using sucrose synthase for UDP-glu-
cose (and UDP-Gal) regeneration, where the co-product
UDP can directly activate the sugar to generate UDP-glu-
cose, oligosaccharide synthesis is intimately dependent
upon cellular metabolism. In the case of sucrose synthase,
the host is not an active player in the synthesis, it merely
provides a milieu in which enzymatic reactions take place.
Carbon metabolism is not needed to provide precursors
or energy source for the oligosaccharide synthesis. This
contrasts with the usual scenario, where a high energy
compound such as UTP, GTP, CTP, ATP, or equivalent
such as PEP is needed for activation of sugars in each cycle
of the reaction. This necessarily brings in the complexity
of central metabolism to the oligosaccharide synthesis.
Consequently, an energy source is needed, and the carbon
flux distributions need to be considered. Since the best
synthesis has been demonstrated with bacterial coupling,
it is instructive to analyze the energy source and carbon
flux for this case. High-energy compounds are produced
from orotic acid by a strain efficient in nucleotide synthe-
sis (Figures 2, 5, and 7). The UTP or other equivalents are
utilized by the coupled E. coli strain(s) engineered to over-
produce sugar nucleotides, which in turn are consumed
by a strain harboring the necessary glycosyltransferases.
This strategy avoids the complication of coupling central
metabolism for energy production with the oligosaccha-
ride synthesis by using multiple types of cells, each with a
specialized role. Although so far this strategy gives the
highest product concentration and provides a realistic
technology for commercialization, the requirement of at
least three fermentations for a single glycosidic bond
makes it a far from ideal solution to a complicated prob-
lem. So logically, one asks whether it is possible to achieve
the same efficiency in a single strain. From a material bal-
ance point of view, the synthesis of an oligosaccharide
does not require a constant supply of a nitrogen source,
such as orotic acid, if the co-product UDP is truly recycled.
It should only require a carbon and energy source to sup-
port the synthesis. A single strain strategy could work as
Metabolic pathway for GDP-fucose synthesis in Saccharomy- ces cerevisiae [17] Figure 8
Metabolic pathway for GDP-fucose synthesis in Saccharomy-
ces cerevisiae [17]. Enzymes – 1: GDP-mannose-4,6-dehy-
dratase (Gmd), 2: GDP-4-keto-6-deoxy-mannose-3,5-
epimerase (GmeR), 3: 4-reductase (GmeR), 4: GDP-fucose 
pyrophosphorylase, 5: fucose kinase.Microbial Cell Factories 2006, 5:25 http://www.microbialcellfactories.com/content/5/1/25
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efficiently as three, four, or five coupled strains. This asser-
tion comes from the observation of microbial polysaccha-
ride synthesis. Polysaccharide synthesis shares much of
the same challenges as oligosaccharide synthesis, being
both carbon and energy intensive. Yet successful microbes
are found to efficiently channel the carbons to polysac-
charides with comparable product yield, product concen-
tration, and productivity to what was reported with the
microbial coupling strategy. Examples of those are curd-
lan-producing Agrobacterium  sp. and xanthan gum-pro-
ducing  Xanthomonas campestris. Therefore, the key to
success for a single strain strategy seems to rely on uncov-
ering the secret of polysaccharide synthesis from these
microbes, particularly with regard to understanding the
coupling of central metabolism to polysaccharide synthe-
sis. The available genome sequences along with pro-
teomic and metablomic tools should facilitate the study
toward this goal.
Host selection
This section only concerns the single strain strategy. A suc-
cessful oligosaccharide synthesis system, as it becomes
clear from the above analysis, requires active glycosyl-
transferases, an efficient in-situ provision mechanism of
donors, internalization of acceptors, and a continuous
supply of energy. A host must be able to express the requi-
site glycosyltransferase enzymes in active forms. Despite
impressive successful examples, this is not always the case,
especially considering that many interesting glycans are of
mammalian-origin. Bacterial glycosyltransferases are
extremely useful to avoid the difficulty in expression, but
one cannot always find a bacterial version of the glycosyl-
transferase enzyme required for the synthesis. Therefore,
expression of active glycosyltransferases is an important
consideration in the choice of a host strain for the meta-
bolic engineering effort. Only a limited number of hosts
were used for oligosaccharide synthesis, mainly those that
have established genetic tools and commercially available
expression vectors.
Donor provision is a tough issue in the engineering proc-
ess. As reviewed in earlier sections, a strategy to use the
cells' natural mechanism for donor regeneration has been
successfully used without much genetic manipulation. On
the other hand, strategies to create new regeneration
mechanisms were also developed. Another interesting
strategy has emerged which uses a host that naturally over-
produces a sugar polymer. By appropriate engineering, the
already efficient mechanism for cofactor regeneration can
be harnessed for oligosaccharides synthesis. This strategy
was illustrated by Rigngenberg et al. in an E. coli strain
producing polysialic acid [21]. A null defect in the gene
encoding polysialyltransferase (neuS) dramatically altered
the sialate metabolism, allowing accumulation of CMP-
sialic acid to a level more than 50 times higher than that
of the wild type. Although this was not demonstrated for
sialyl-oligosaccharide synthesis, it is conceivable that by
expressing a sialyltransferase and providing a suitable
acceptor, the strain could be used for sialyl-oligosaccha-
ride synthesis. In the authors' lab, an Agrobacterium sp.
strain, naturally overproducing curdlan (a β1,3-glucose
homopolymer), was engineered for UDP-galactose regen-
eration by reducing glucose polymerization. Although the
UDP-glucose pool was not significantly elevated by the
mutation, oligosaccharide synthesis was much higher
than that in an E. coli strain under comparable conditions
[22]. These examples show that judicious selection of a
host strain can lead to an efficient system without overex-
pression of the enzymes involved in cofactor regenera-
tion. The use of naturally evolved strains for sugar
nucleotide regeneration is superior in not only minimiz-
ing the genetic modification and resulting metabolic bur-
den of recombinant protein expression, but also ensuring
optimal pathway interaction.
Overall, the in-situ provision of donors, acceptor access,
and interaction of central metabolism for oligosaccharide
synthesis require significant host modification beyond
high expression of certain enzymes; therefore, the amena-
bility of the host to genetic engineering is an important
consideration in the choice of a host. Broad-host-range
expression vectors can be developed for gram-negative
bacteria, which allow the introduction of novel enzymes
into a wide range of strains, widening the selection of host
strains.
Polysaccharides
The following sections highlight recent metabolic engi-
neering efforts in improving production of sugar poly-
mers. Space constraints make it necessary for us to limit
the review to only a few polymers.
Hyaluronan
Hyaluronic acid (HA) or hyaluronan is a linear polymer of
a repeating disaccharide unit, glucuronic acid (GlcA) and
N-acetyl-glucosamine (GlcNAc). It is found in all verte-
brates as a major constituent of the extracellular matrices.
In animals, it is found in the vitreous body of the eye, the
synovial fluid of articular joints, and the intercellular
space of the epidermis. HA is believed to be a lubricant
between joint surfaces. It is also involved in morphogene-
sis and differentiation. Additionally, HA interacts with
proteins such as CD44, RHAMM, and fibrinogen, influ-
encing many biological processes such as angiogenesis,
cancer, cell motility, wound healing, and cell adhesion
[23]. Due to these varied roles, HA influences cell behav-
ior and has significant structural, rheological, physiologi-
cal, and biological functions in the body. Its distinctive
viscoelastic properties, coupled with its lack of immuno-
genicity and toxicity, have led to a wide range of applica-Microbial Cell Factories 2006, 5:25 http://www.microbialcellfactories.com/content/5/1/25
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tions in the cosmetic and medicinal fields, including skin
moisturizers, osteoarthritis treatment, ophthalmic sur-
gery, adhesion prevention after abdominal surgery, and
wound healing [24]. HA can be either extracted from
rooster combs or obtained through fermentation with
strains of group C Streptococcus. In rooster combs, HA is
complexed with proteoglycans, making the isolation of
high purity, high molecular weight HA costly [25]. In
addition, animal-derived therapeutics carry the risk of
transmitting viruses and other adventitious agents as well
as inducing immunogenic and inflammatory responses.
Due to difficulties in genetic engineering, the Streptococcus
fermentation route is far from ideal despite its long his-
tory as a production strain of HA.
HA is synthesized from two precursors, UDP-glucuronic
Acid (UDP-GA) and UDP-N-acetylglucosamine (UDP-
GlcNAc), by a polymerase called hyaluronan synthase
(encoded by hasA). UDP-GA can be obtained from oxida-
tion of UDP-glucose, which is catalyzed by the NADH-
dependent UDP-glucose dehydrogenase. Both UDP-glu-
cose and UDP-GlcNAc are precursors for cell wall biosyn-
thesis. HA synthesis therefore competes with cell growth.
Recognizing the high energy demand of HA synthesis,
metabolic engineering of Streptococcus to improve energy
production was attempted by overexpressing NADH oxi-
dase (NOX) and thereby shifting the metabolism from
lactate-producing to acetate-producing (energy making)
mixed fermentation. This strategy successfully increased
the ATP yield by 30%. However, it only led to a 15% bio-
mass increase instead of the desired increase in HA syn-
thesis [26]. This illustrates the difficulty of improving
production of a product whose synthesis competes with
biomass synthesis in precursor and energy requirements.
A successful metabolic engineering strategy will necessar-
ily delineate biomass production from HA synthesis.
Other metabolic engineering efforts have been focused on
developing suitable microbial production strains.
Recently, Novozyme has developed a production system
with a Bacillus subtilis strain [24]. Although there are no
benefits in productivity and HA molecular weight as com-
pared to the Streptococcus fermentation, Bacillus is a better
production strain as it is a GRAS (generally regarded as
safe) and the HA produced is not cell-associated, facilitat-
ing downstream processing [26]. Another HA synthesis
system was developed using chlorella cells infected with
Chlorovirus [23]. The yield is about 10 times lower than
that of other microbial systems. However, a potential
advantage of the system is the higher molecular weight
product. This is important as many HA applications are
molecular weight dependent. In fact, higher molecular
weight HA is highly prized in medical applications such as
eye surgery. Derivation of a production strain capable of
making high molecular weight HA with mono-dispersity
is a holy grail for metabolic engineering efforts. The suc-
cess of such endeavors awaits a full understanding of the
chain termination mechanisms in HA polymer synthesis.
Alginate
Alginate is a linear copolymer of two-sugar residues, β-D-
mannuronic acid (M) and α-L-guluronic acid (G), linked
together by 1–4 linkages [27]. The industrially important
polymer is produced commercially by extraction from
brown seaweeds. Several microbes, such as Psudomonas
aruginosa  and  Azotobacter vinelandii, naturally produce
alginate, and a microbial production method could
potentially be developed. As properties of the polymer
vary widely with the monomer sugar sequence, microbial
systems offer exciting opportunities to produce tailor-
made polymers with desired properties. Key to the success
of such endeavors is the understanding of enzyme func-
tions involved in alginate synthesis. Of particular interest
is the mannuronan C-5-epimerase, which catalyzes post-
polymerization conversion of M residues to G residues.
Although  Psudomonas aruginosa encodes only one such
enzyme, Azotobacter vinelandii has up to 8 epimerases that
differ in how the epimerization is introduced, leading to
either alternating or G blocks (stretches of consecutive G
residues) of different lengths, and thereby considerable
diversity of the structure and property. These enzymes
have interesting composite structures, containing multi-
ple copies of domains of different functions. This struc-
tural feature provides particularly good metabolic
engineering targets for rational engineering of polymer
properties, provided that the gene-to-enzyme activity rela-
tionships are understood in sufficient detail.
Exopolysaccharides for food use
Exopolysaccharides (EPS) made by bacteria such as Lacto-
coccus and Streptococcus are an active subject of metabolic
engineering. These organisms are widely used in dairy
product production. In-situ exopolysaccharide synthesis
allows modulation of rheology, improved mouthfeel, and
textures of food products. It can also impart some health
benefits as prebiotics. However, EPS represents significant
metabolic engineering challenges as the natural produc-
tion level is generally quite low, 50–400 mg/L, when com-
pared to other food-grade polysaccharides such as
xanthan (25 g/L, [28]) and curdlan (93 g/L, [29]) made by
non-dairy organisms. Metabolic engineering efforts in
improving EPS production have been directed to precur-
sor synthesis. Overexpression of UDP-glucose pyrophos-
phorylase (GalU), an enzyme involved in UDP-glucose
synthesis and under the control of a nisin inducible pro-
moter, increased the enzyme specific activity in Lactococcus
lactis by 20-fold, which in turn increased both UDP-glu-
cose and UDP-galactose synthesis by eight-fold. However,
the increased enzyme specific activities did not signifi-
cantly enhance the synthesis of EPS [30]. Similarly, over-
expression of the phosphoglucomutase gene (pgm) inMicrobial Cell Factories 2006, 5:25 http://www.microbialcellfactories.com/content/5/1/25
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Sphingomonas, led to a six-fold increase in enzyme specific
activity, yet only a small percentage of increase in exopol-
ysaccharides [31]. It appears that, at least in these two
examples, the level of precursors was not limiting the EPS
synthesis. However, overexpression of both PGM (the
enzyme catalyzing the conversion of glucose-6-phosphate
to glucose-1-phosphate) and GalU in Streptococcus ther-
mophilus led to a two-fold increase in EPS synthesis [32].
Further increase (50%) was obtained when Leloir enzyme
(GalK, GalT, and GalU) activities were also increased.
While precursor synthesis and interaction with central
metabolism are the main focus, other metabolic engineer-
ing strategies were also pursued. The increase in the
expression of biosynthetic gene cluster in Sphingomonas
(including glycosyltransferase enzyme activity), for exam-
ple, improved EPS synthesis by 20% [31]. Further
improvement in the production level, an order of magni-
tude improvement, is desirable for most applications.
Therefore, significant challenges still lie ahead. Poten-
tially, not only can the production level be increased, but
the composition of EPS could be modified or tailored to
target applications.
Conclusion
Tremendous progress has been made in recent years in
complex carbohydrate synthesis. Metabolic engineering
has provided the tools for development of highly efficient
microbial whole-cell catalysts for oligosaccharide and
polysaccharide synthesis. Product concentrations as high
as 188 g/L were obtained with engineered strains. An
important advantage of using metabolically engineered
whole-cell catalyst versus other approaches is the ability to
use inexpensive starting material. Consequently, the syn-
thesis could be readily scaled-up according to need. Many
valuable oligosaccharides have now been available in
gram or larger quantities at realistic costs. An economic
analysis puts the cost of oligosaccharide synthesis at $30–
50/g [10]. This indeed should be hailed as a significant
achievement of metabolic engineering. However, signifi-
cant challenges still lie ahead. Although the structures syn-
thesized through the engineered strains listed in Table 1
(see Additional file 1) are very impressive, they are only a
small fraction of nature's diversity. Many structures of
medical importance still await an efficient method for
synthesis. For those structures already successfully synthe-
sized, it is important to achieve high efficiency of synthe-
sis in a single strain, as opposed to using coupled
microbes, to make the process economically viable.
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galactose, GKDM: guanosine diphosphate-4-keto-6-
deoxy-mannnose, Glc: glucose, Glc-1-P: glucose-1-phos-
phate, Glc-6-P: glucose-6-phosphate, GlcNAc: N-
acetylglucosamine, GMP: guanosine monophosphate,
GTP: guanosine triphosphate, HA: hyaluronic acid, Lac-
NAc:  N-acetyllactosamine, Man-1-P: mannose-1-phos-
phate, Man-6-P: mannose-6-phosphate, ManNAc: N-
acetylmannosamine, NADP: nicotinamide adenine dinu-
cleotide phosphate (oxidized), NADPH: nicotinamide
adenine dinucleotide phosphate (reduced), NeuAc: N-
acetylneuraminic acid, PEP: phosphoenolpyruvate, Pi:
inorganic phosphate, PPi: pyrophosphate, UDP: uridine
diphosphate, UDP-GA: uridine diphosphate-glucuronic
acid, UDP-Gal: uridine diphosphate-galactose, UDP-Gal-
NAc: uridine diphosphate-N-acetylgalactosamine, UDP-
Glc: uridine diphosphate-glucose, UDP-GlcNAc: uridine
diphosphate-N-acetylglucosamine, UMP: uridine mono-
phosphate, UTP: uridine triphosphate.
Additional material
Acknowledgements
Work in the authors' lab is supported by National Science Foundation and 
the American Cancer Society. A. Ruffing acknowledges a NSF graduate fel-
lowship.
References
1. Wong C-H, Whitesides GM: Enzymes in Synthetic Organic
Chemistry.  Volume 12. 1st edition. New York: Oxford . 
2. Perugino G, Trincone A, Rossi M, Moracci M: Oligosaccharide syn-
thesis by glycosynthases.  Trends in Biotechnology 2004,
22(1):31-37.
3. Saxon E, Bertozzi CR: Chemical and biological strategies for
engineering cell surface glycosylation.  Annual Review of Cell and
Developmental Biology 2001, 17:1-23.
4. Flitsch SL: Chemical and enzymatic synthesis of glycopoly-
mers.  Current Opinion in Chemical Biology 2000, 4(6):619-625.
5. Koeller KM, Wong CH: Complex carbohydrate synthesis tools
for glycobiologists: enzyme-based approach and program-
mable one-pot strategies.  Glycobiology 2000, 10(11):1157-1169.
6. Crout DH, Vic G: Glycosidases and glycosyl transferases in gly-
coside and oligosaccharide synthesis.  Current Opinion in Chemical
Biology 1998, 2(1):98-111.
7. Meynial-Salles I, Combes D: In vitro glycosylation of proteins: An
enzymatic approach.  Journal of Biotechnology 1996, 46(1):1-14.
8. Koizumi S, Endo T, Tabata K, Ozaki A: Large-scale production of
UDP-galactose and globotriose by coupling metabolically
engineered bacteria.  Nature Biotechnology 1998, 16:847-850.
Additional File 1
Table 1: Oligosaccharides synthesized by metabolically engineered 
microbes from 1998 to present. Table 1 provides a comprehensive list of 
oligosaccharides synthesized by metabolically engineered microbes from a 
review of literature since 1998.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1475-
2859-5-25-S1.doc]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Microbial Cell Factories 2006, 5:25 http://www.microbialcellfactories.com/content/5/1/25
Page 9 of 9
(page number not for citation purposes)
9. Liu Z, Lu Y, Zhang J, Pardee K, Wang PG: P1 trisaccharide
(Galα1,4Galβ1,4GlcNAc) synthesis by enzyme glycosylation
reactions using recombinant Escherichia coli.  Applied and Envi-
ronmental Microbiology 2003, 69(4):2110-2115.
10. Zhang J, Kowal P, Chen X, Wang PG: Large-scale synthesis of glo-
botriose derivatives through recombinant E. coli.  Org Biomol
Chem 2003, 1:3048-3053.
11. Bettler E, Imberty A, Priem B, Chazalet V, Heyraud A, Joziasse DH,
Geremia RA: Production of recombinant xenotransplantation
antigen in Escherichia coli.  Biochemical and Biophysical Research
Communications 2003, 302:620-624.
12. Mao Z, Shin H-D, Chen RR: Engineering the E. coli UDP-glucose
synthesis pathway for oligosaccharide synthesis.  Biotechnology
Progress 2006, 22:369-374.
13. Priem B, Gilbert M, Wakarchuk WW, Heyraud A, Samain E: A new
fermentation process allows large-scale production of
human milk oligosaccharides by metabolically engineered
bacteria.  Glycobiology 2002, 12(4):235-240.
14. Endo T, Koizumi S, Tabata K, Ozaki A: Large-scale production of
CMP-NeuAc and sialylated oligosaccharides through bacte-
rial coupling.  Applied Microbiology & Biotechnology 2000, 53:257-261.
15. Dumon C, Priem B, Martin SL, Heyraud A, Bosso C, Samain E: In vivo
fucosylation of lacto-N-neotetraose and lacto-N-neohexaose
by heterologous expression of Helicobacter pylori α-1,3 fuco-
syltransferase in engineered Escherichia coli.  Glycoconjugate
Journal 2001, 18:465-474.
16. Koizumi S, Endo T, Tabata K, Nagano H, Ohnishi J, Ozaki A: Large-
scale production of GDP-fucose and Lewis X by bacterial
coupling.  Journal of Industrial Microbiology & Biotechnology 2005,
25:213-217.
17. Mattila P, Rabina J, Hortling S, Helin J, Renkonen R: Functional
expression of Escherichia coli enzymes synthesizing GDP-L-
fucose from inherent GDP-D-mannose in Saccharomyces cer-
evisiae.  Glycobiology 2000, 10(10):1041-1047.
18. Cottaz S, Samain E: Genetic engineering of Escherichia coli for
the production of NI, NII-diacetylchitobiose (chitinbiose) and
its utilization as a primer for the synthesis of complex carbo-
hydrates.  Metabolic Engineering 2005, 7:311-317.
19. Antoine T, Priem B, Heyraud A, Greffe L, Gilbert M, Wakarchuk
WW, Lam JS, Samain E: Large-Scale in vivo synthesis of the car-
bohydrate moieties of gangliosides GM1 and GM2 by meta-
bolically engineered Escherichia coli.  ChemBioChem 2003,
4:406-412.
20. Bettler E, Samain E, Chazalet V, Bosso C, Heyraud A, Joziasse DH,
Wakarchuk WW, Imberty A, Geremia RA: The living factory: In
vivo production of N-acetyllactosamine containing carbohy-
drates in E. coli.  Glycoconjugate Journal 1999, 16:205-212.
21. Ringenberg M, Lichtensteiger C, Vimr E: Redirection of sialic acid
metabolism in genetically engineered Escherichia coli.  Glyco-
biology 2001, 11(7):533-539.
22. Ruffing A, Mao Z, Chen RR: Metabolic engineering of Agrobacte-
rium sp. for UDP-galactose regeneration and oligosaccharide
synthesis.  Metabolic Engineering 2006 in press.
23. Yamada T, Kawasaki T: Microbial synthesis of hyaluronan and
chitin: New approaches.  Journal of Bioscience and Bioengineering
2005, 99(6):521-528.
24. Widner B, Behr R, Von Dollen S, Tang M, Heu T, Sloma A, Sternberg
D, DeAngelis PL, Weigel PH, Brown S: Hyaluronic acid produc-
tion in Bacillus subtilis.  Applied and Environmental Microbiology 2005,
71(7):3747-3752.
25. Blank LM, McLaughlin RL, Nielsen LK: Stable production of
hyaluronic acid in Streptococcus zooepidemicus chemostats
operated at high dilution rate.  Biotechnology and Bioengineering
2005, 90(6):685-693.
26. Chong BF, Blank LM, Mclaughlin R, Nielsen LK: Microbial
hyaluronic acid production.  Applied Microbiology & Biotechnology
2005, 66(4):341-351.
27. Ertesvag H, Hoidal HK, Schjerven H, Svanem BI, Valla S: Mannuro-
nan C-5-epimerases and their application for in vitro and in
vivo design of new alginates useful in biotechnology.  Metabolic
Engineering 1999, 1(3):262-269.
28. van Kranenburg R, Boels IC, Kleerebezem M, de Vos WM: Genetics
and engineering of microbial exopolysaccharides for food:
Approaches for the production of existing and novel polysac-
charides.  Current Opinion in Biotechnology 1999, 10(5):498-504.
29. Lee J-h, Lee IY: Optimization of uracil addition for curdlan (β-
1→3-glucan) production by Agrobacterium sp.  Biotechnology Let-
ters 2001, 23:1131-1134.
30. Boels IC, Ramos A, Kleerebezem M, de Vos WM: Functional anal-
ysis of the Lactococcus lactis galU and galE genes and their
impact on sugar nucleotide and exopolysaccharide biosyn-
thesis.  Applied and Environmental Microbiology 2001,
67(7):3033-3040.
31. Thorne L, Mikolajczak MJ, Armentrout RW, Pollock TJ: Increasing
the yield and viscosity of exopolysaccharides secreted by
Sphingomonas by augmentation of chromosomal genes with
multiple copies of cloned biosynthetic genes.  Journal of Indus-
trial Microbiology & Biotechnology 2000, 25:49-57.
32. Levander F, Svensson M, Radstrom P: Enhanced exopolysaccha-
ride production by metabolic engineering of Streptococcus
thermophilus.  Applied and Environmental Microbiology 2002,
68(2):784-790.